Biotech RadarJobs updated

COMPANY

Sonoma Biotherapeutics

HQ: South San Francisco, CA source · sonomabio.com ↗

Clinical Phase 1

Company-reported stage: Phase 1 · source · Oct 12, 2026

Keywords: rheumatoid arthritis cell therapy immunology Hidradenitis Suppurativa SBT777101 SBT115301

Location: South San Francisco, CA · source · Aug 11, 2021

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

  1. Partnership Partnership / licensing announced Jul 13, 2026. Source: company's own press page. source ↗
  2. Trial start —: A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic source ↗
  3. Trial start Phase 1: Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa source ↗
  4. Trial start Phase 1: Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis source ↗
  5. Trial start Phase 1: Study of Single Doses of SBT115301 in Healthy Participants source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT06201416Study of Single Doses of SBT777101 in Subjects With Rheumatoid ArthritisPhase 1RecruitingMar 6, 20242026-11 (estimated)
NCT07123038A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) TherapeuticNot listedRecruitingJul 22, 20252040-12 (estimated)
NCT06361836Study of Single Doses of SBT777101 in Subjects With Hidradenitis SuppurativaPhase 1Active, not recruitingOct 9, 20242026-11 (estimated)
NCT05388981Study of Single Doses of SBT115301 in Healthy ParticipantsPhase 1CompletedJul 25, 2022Jan 3, 2024 (actual)
Feedback